Abstract:BackgroundOne of the mechanisms by which tumors evade immune surveillance is through shedding of the major histocompatibility complex (MHC) class I chain-related protein A and B (MICA/B) from their cell surface. MICA/B are ligands for the activating receptor NKG2D on NK and CD8 T cells. This shedding reduces cell surface levels of MICA/B and impairs NKG2D recognition. Shed MICA/B can also mask NKG2D receptor and is thought to induce NKG2D internalization, further compromising immune surveillance by NK cells.MethodsWe isolated human primary NK cells from normal donors and tested the suppressive activity of soluble recombinant MICA in vitro. Utilizing a panel of novel anti-MICA antibodies, we further examined the stimulatory activities of anti-MICA antibodies that reversed the suppressive effects of soluble MICA.ResultsWe show that suppressive effects of soluble MICA (sMICA) on NK cell cytolytic activity was not due to the down-regulation of cell surface NKG2D. In the presence of an α3 domain-specific MICA antibody, which did not obstruct NKG2D binding, sMICA-mediated NK cell suppression was completely reversed. Reversal of NK cell inhibition by sMICA was mediated by immune complex formation that agonized NKG2D signaling. Furthermore, this restorative activity was dependent on antibody Fc effector function as the introduction of Fc mutations to abrogate Fc receptor binding failed to reverse sMICA-mediated NK cell suppression. Furthermore, MICA immune complexes preformed with an α3 domain-specific antibody (containing a wild-type Fc) induced IFN-γ and TNF-α secretion by NK cells in the absence of cancer cells, whereas MICA immune complexes preformed with the Fc effectorless antibody failed to induce IFN-γ and TNF-α secretion. Finally, we demonstrated that MICA immune complexes formed with the α3 domain-specific antibody activates NKG2D on NK cells leading to the release of IFN-γ.ConclusionsOur results demonstrate that an α3 domain-specific MICA antibody can circumvent sMICA-mediated suppression of NK cell cytolytic activity. Moreover, our data suggest that MICA immune complexes formed with α3-specific antibodies can activate NKG2D receptor and restore NK cell function in a Fc-dependent manner. The clinical utility of α3 domain-specific MICA/B antibodies may hold great promise as a new strategy for cancer immunotherapy.

Primary Study on the Immune Evasion Mechanism in Acute Leukemia Mediated by the Active Receptor of NK Cell NKG2D and the Ligand MICA/B

[Expression and Abscission of Activated Receptors and Their Ligands On/from NK Cells in Peripheral Blood of Patients with Acute Leukemia].

The immunosurveillance and immune escape are related with NKG2D receptor in leukemia patients

Study on IFN-γ and IL-10 of the Acute Leukemia

Impact on NK cell functions of acute versus chronic exposure to extracellular vesicle‐associated MICA: Dual role in cancer immunosurveillance

Analysis of the expression of MICA on tumor cell lines of different histotypes and their sensitivity to NK cytotoxicity

Defective NK Cells in Acute Myeloid Leukemia Patients at Diagnosis Are Associated with Blast Transcriptional Signatures of Immune Evasion

Acute Myeloid Leukemia Epigenetic Immune Escape From Nature Killer Cells by ICAM-1

NKG2D and MICA/B shedding: a ‘tag game’ between NK cells and malignant cells

The Opposite Effect of Mmica and Rmica on the Expression of NKG2D and the Influence on NK Cell Receptor Repertoire

Abstract 3803: Immune escape from NK cells and activated CD8 T cells by miR-183 repression of MICA/B expression in human lung cancer

Imbalance of NKG2D and its inhibitory counterparts: how does tumor escape from innate immunity?

Immune Evasion and Therapeutic Opportunities Based on Natural Killer Cells.

MICA immune complex formed with alpha 3 domain-specific antibody activates human NK cells in a Fc-dependent manner

Study on the Immune Escape Mechanism of Acute Myeloid Leukemia With DNMT3A Mutation

Immune evasion by TGFβ-induced miR-183 repression of MICA/B expression in human lung tumor cells

A potential mechanism of tumor immune escape: Regulation and application of soluble natural killer group 2 member D ligands (Review)

Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation

Data from Inhibition of MICA and MICB Shedding Elicits NK-Cell–Mediated Immunity Against Tumors Resistant to Cytotoxic T Cells

Natural killer group 2D receptor and its ligands in cancer immune escape

Soluble NKG2DLs Are Elevated in Breast Cancer Patients and Associate with Disease Outcome